Autolus Therapeutics plc AUTL
Set alert
As of Nov 2, 1:03 PM ET
- YTD
- -27.69%
- 1 year
- -7.16%
- Open
- 1.55
- Prev close
- 1.52
- Mkt cap
- 383.11M
- Vol
- 1.96M
- Avg vol
- 2.28M
- EPS
- -1.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.42
- High
- 1.56
- Forward P/E
- -3.08
- Beta
- 0.00
- Short ratio
- 2.48
- Inst. own
- 77.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.39
- 200-d avg
- 4.08
- 1y target
- 10.45
5D chart
Signals (49)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 12:05 PM | 58 minutes ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 11:35 AM | 1 hour ago |
| RSI: Oversold | Nov 2, 11:15 AM | 1 hour ago |
| RSI: Oversold | Nov 2, 10:55 AM | 2 hours ago |
| MACD: Sell Signal | Nov 2, 10:30 AM | 2 hours ago |
| MACD: Buy Signal | Nov 2, 10:25 AM | 2 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 2 hours ago |
| MACD: Sell Signal | Nov 2, 10:00 AM | 3 hours ago |
| MACD: Buy Signal | Oct 30, 3:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 4 days ago |
| RSI: Oversold | Oct 29, 11:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 5 days ago |
| RSI: Overbought | Oct 28, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
News
-
6 hours ago benzinga.com
HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.
6 days ago seekingalpha.com
Autolus Therapeutics: Key Questions For The Near Term
Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing autoimmune pipeline catalysts. Q2 2026 saw product revenue rise to $45.7M, with net loss narrowing and…
6 days ago globenewswire.com
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…
4 weeks ago zacks.com
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-
4 weeks ago benzinga.com
Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today…
4 weeks ago globenewswire.com
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
1 month ago defenseworld.net
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
-
1 month ago benzinga.com
The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of…
1 month ago globenewswire.com
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
2 months ago seekingalpha.com
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Autolus Therapeutics Q2 Earnings Call Highlights
Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year…
-
2 months ago benzinga.com
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
-
2 months ago benzinga.com
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses…
3 months ago globenewswire.com
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
3 months ago benzinga.com
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.
-
3 months ago benzinga.com
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-dateFY 2026 sales guidance increased to $140 – $150…
3 months ago globenewswire.com
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150…
3 months ago seekingalpha.com
Autolus Therapeutics: Navigating A Bumpy 2026
Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis…
3 months ago zacks.com
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
4 months ago globenewswire.com
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
4 months ago globenewswire.com
Autolus Therapeutics to Participate in Upcoming Investor Conference
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
4 months ago globenewswire.com
Autolus Therapeutics Receives Prix Galien UK Award
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
4 months ago zacks.com
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings…
5 months ago zacks.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average…
5 months ago globenewswire.com
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
5 months ago globenewswire.com
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
5 months ago benzinga.com
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
5 months ago seekingalpha.com
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10
HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.
5 months ago benzinga.com
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est
Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.062 million analyst estimate.
-
5 months ago benzinga.com
Autolus Therapeutics Q1 EPS $(0.27), Inline, Sales $26.218M Beat $26.160M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the…
7 months ago benzinga.com
Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
-
7 months ago benzinga.com
Earnings Scheduled For March 27, 2026
Earnings Scheduled For March 27, 2026
9 months ago benzinga.com
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
10 months ago benzinga.com
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
10 months ago benzinga.com
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
10 months ago benzinga.com
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday
11 months ago benzinga.com
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
1 year ago benzinga.com
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday